Correlation Between GeneReach Biotechnology and Optivision Technology

Can any of the company-specific risk be diversified away by investing in both GeneReach Biotechnology and Optivision Technology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GeneReach Biotechnology and Optivision Technology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between GeneReach Biotechnology and Optivision Technology, you can compare the effects of market volatilities on GeneReach Biotechnology and Optivision Technology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GeneReach Biotechnology with a short position of Optivision Technology. Check out your portfolio center. Please also check ongoing floating volatility patterns of GeneReach Biotechnology and Optivision Technology.

Diversification Opportunities for GeneReach Biotechnology and Optivision Technology

-0.22

Correlation Coefficient

GeneReach Biotechnology  Optivision Technology

Very good diversification

The 3 months correlation between GeneReach and Optivision is -0.22. Overlapping area represents the amount of risk that can be diversified away by holding GeneReach Biotechnology and Optivision Technology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Optivision Technology and GeneReach Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GeneReach Biotechnology are associated (or correlated) with Optivision Technology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Optivision Technology has no effect on the direction of GeneReach Biotechnology i.e., GeneReach Biotechnology and Optivision Technology go up and down completely randomly.

Pair Corralation between GeneReach Biotechnology and Optivision Technology

Assuming the 90 days trading horizon GeneReach Biotechnology is expected to under-perform the Optivision Technology. In addition to that, GeneReach Biotechnology is 1.17 times more volatile than Optivision Technology. It trades about -0.12 of its total potential returns per unit of risk. Optivision Technology is currently generating about 0.14 per unit of volatility. If you would invest  3,020  in Optivision Technology on December 26, 2024 and sell it today you would earn a total of  345.00  from holding Optivision Technology or generate 11.42% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

GeneReach Biotechnology  vs.  Optivision Technology

GeneReach Biotechnology

Risk-Adjusted Performance

Very Weak

Over the last 90 days GeneReach Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Optivision Technology

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Optivision Technology are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Optivision Technology showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with GeneReach Biotechnology and Optivision Technology

The main advantage of trading using opposite GeneReach Biotechnology and Optivision Technology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GeneReach Biotechnology position performs unexpectedly, Optivision Technology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Optivision Technology will offset losses from the drop in Optivision Technology's long position.

The idea behind GeneReach Biotechnology and Optivision Technology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.